Our study creates new avenues for overcoming gefitinib resistance by showing that molecules that inhibit the nuclear functions of PKM2 or disrupt STAT3 association with PKM2 in the nucleus may increase the sensitivity of CRC cells to gefitinib. The gene discussed is STAT3; the disease is colorectal carcinoma.